KRAS and familial pancreatic carcinoma: They also counteract the finding that HIPK2 overexpression reduces ERK phosphorylation and pancreatic cancer proliferation, making HIPK2 a suitable target for inhibiting KRAS/ERK activation in pancreatic cancer [66].